CD4 and neoplasm: Here, assessment of immunophenotypic changes across the different treatment arms clearly showed that, in tumours responding to ⍺PD1 or OXA (when administered as a monotherapy or in combination), the most significant differences in immune cells were observed for tumour-infiltrating CD8+ T-cells, tumour infiltrating CD8+ TEM cells and CD4+ TEM cells (Figure 3A–E, Table 2).